During a live event, Jeffrey V. Matous, MD, discussed flexible dosing and the need to expand use in community practices for ...

Explore the innovative subcutaneous delivery of isatuximab for multiple myeloma, enhancing patient experience and treatment ...

Karolinska University Hospital has, for the first time in Sweden, begun preparations to treat a patient with multiple myeloma ...

Karolinska University Hospital has, for the first time in Sweden, begun preparations to treat a patient with multiple myeloma ...

In fact, 1 in 5 myeloma patients are diagnosed with the disease only because they’ve gone to the doctor for routine medical exams and had lab tests that revealed telltale changes in blood or ...

According to clinical guidelines, high-risk myeloma patients should receive intensified treatment regimens. However, heterogeneity in cli ...

Multiple Myeloma Research. Our multiple myeloma research begins in the laboratory, where we study the biology of myeloma cells and develop potential new drugs and immunotherapies. It also includes ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without detectable cancer for years after facing certain death.

A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma, according to data presented at the annual meeting of the American Society of Clinical ...

Multiple myeloma is a cancer in plasma cells that affects 32,000 individuals in the United ... a postdoctoral fellow in the Ghobrial lab; Andrea Poletti, a post-doctoral fellow at the ...

Along with co-first authors Ankit Dutta, PhD, a postdoctoral fellow in the Ghobrial lab, Andrea Poletti, PhD, a post-doctoral fellow at the University of Bologna, Italy, and collaborators from the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic products, today announced the availability of its first Laboratory ...